Please note that this summary was posted more than 5 years ago. More recent research findings may have been published.
This is a plain English summary of an original research article. The views expressed are those of the author(s) and reviewer(s) at the time of publication.
This review found that giving an anti-sickness drug, like ondansetron, before propofol, an anaesthetic, helped reduce the frequency and severity of injection pain.
The intravenous anaesthetic propofol is used at the start of almost all general anaesthetics in the UK but it does often cause unpleasant pain when it is injected.
This review of trials looked for trials of any drug in the group of commonly-used anti-sickness drugs called 5HT3 receptor antagonists. Ondansetron, one of these drugs, is often used during anaesthesia to reduce nausea and vomiting after waking, but is usually given after the anaesthetic injection.
All eight trials in this review were conducted in Asia on adults. One of the antagonist drugs used (in about 20% of those studied) is not currently available in the UK, reducing direct relevance.
The findings suggest that a simple change in sequence of commonly used drugs could improve patient comfort.
Why was this study needed?
Propofol is the most commonly used intravenous anaesthetic to send people to sleep before surgery in the UK.
Up to 60% of people experience pain at the site of injection and infusion – usually the back of the hand. While this pain is likely to be modest, reducing discomfort could help some people, particularly children, for whom pain is more distressing, and those who have many operations. Other ways of reducing propofol injection pain have been tried, such as warming the drug or mixing it with lidocaine but these don’t work particularly well.
Nausea is a common problem after anaesthesia. Drugs known as 5-HT3 receptor antagonists, such as ondansetron are often used to reduce nausea. This review investigated the effectiveness and safety of 5-HT3 receptor antagonists at reducing propofol injection pain, compared with salt solution control. Some trials compared it to lidocaine.
What did this study do?
This was a systematic review and meta-analysis of eight randomised controlled trials containing 834 adults.
To be included in the review trials needed to assess changes in the incidence and intensity of propofol injection pain between injected 5-HT3 receptor antagonist drugs compared with salt-solution. Four of the eight trials also compared lidocaine against salt solution.
The trial 5-HT3 receptor antagonist drugs were ondansetron (282 patients), granisetron (292 patients), ramosetron (180 patients) and palonosetron (80 patients).
All eight trials were carried out in Asia (Korea, Iran and India). Ramosetron is not currently available in the UK, which somewhat reduces the applicability of the results.
What did it find?
- Pre-treatment with 5-HT3 receptor antagonist drugs, compared with the control, reduced the likelihood of propofol injection pain by an average of 57% across all eight trials (relative risk 0.43, 95% confidence interval 0.33 to 0.56).
- In absolute terms 34.1% of those given salt solution reported no pain compared with 77.2% given the drugs.
- There were no reported differences in side effects, and no patient reported pain or discomfort associated with the 5-HT3 receptor antagonist drug injection.
- Combined findings from the four trials comparing 5-HT3 receptor antagonist drugs with lidocaine showed no significant difference in likelihood of experiencing propofol injection pain or reducing its severity.
What does current guidance say on this issue?
UK guidance on minimum standards of sedation practice for healthcare was published in 2013. However, there is no guidance specifically on using 5-HT3 receptor antagonist drugs for the purpose of reducing propofol injection pain. Ondansetron, granisetron and palonosetron are currently marketed in the UK as anti-sickness drugs, while ramosetron is not currently licensed in the UK at all. Mixing of lidocaine with propofol, although commonly practiced, is outside the product licence for each drug.
What are the implications?
Using 5-HT3 receptor antagonists to prevent or reduce propofol injection-related pain, on top of their existing use to prevent post-operative sickness and nausea, could be a useful new dual-use.
Further research should better establish the effectiveness and safety of these drugs in children and other groups in this country at high risk of propofol injection pain.
Citation and Funding
Wang W, Zhou L, Wu L, et al. 5-HT Receptor Antagonists for Propofol Injection Pain: A Meta-Analysis of Randomized Controlled Trials. Clin Drug Investig. 2016;36(4):243-53.
No funding information was provided for this study.
Bibliography
Euasobhon P, Dej-arkom S, Siriussawakul A, et al. Lidocaine for reducing propofol-induced pain on induction of anaesthesia in adults. Cochrane Database of Syst Rev. 2016;(2):CD007874.
Produced by the University of Southampton and Bazian on behalf of NIHR through the NIHR Dissemination Centre
NIHR Evidence is covered by the creative commons, CC-BY licence. Written content and infographics may be freely reproduced provided that suitable acknowledgement is made. Note, this licence excludes comments and images made by third parties, audiovisual content, and linked content on other websites.
